Breaking News Bar

Business News and Information

Peninsula startup’s all-star lineup, fresh off $197M round, circles next-generation cell therapies against cancer, other diseases

The former StartX accelerator company has raised $300 million over four years with the hopes of taking cell therapies into genetic diseases and autoimmune disorders.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear